Double-Blind Placebo-Controlled Pilot Investigation of the Safety of a Single Dose of Rapid-Acting Intranasal Insulin in Down Syndrome

Michael Rosenbloom, Terry Barclay, Justin Johnsen, Lauren Erickson, Aleta Svitak, Maria Pyle, William Frey, Leah R Hanson, Michael Rosenbloom, Terry Barclay, Justin Johnsen, Lauren Erickson, Aleta Svitak, Maria Pyle, William Frey, Leah R Hanson

Abstract

Background: Individuals with Down syndrome are likely to develop clinical and neuropathological brain changes resembling Alzheimer's disease dementia by the ages of 35-40 years. Intranasal insulin is a potential treatment for neurodegenerative disease that has been shown to reduce amyloid plaque burden and improve verbal memory performance in normal as well as memory-impaired adults. Investigations have shown that rapid-acting insulins may result in superior cognitive benefits compared with regular insulin.

Objectives: The primary objective of this study was to measure the safety and feasibility of intranasal rapid-acting glulisine in subjects with Down syndrome. Secondarily, we estimated the effects of intranasal glulisine on cognition and memory in Down syndrome.

Methods: A single-center, single-dose, randomized, double-blind, placebo-controlled, cross-over pilot study was performed to test the safety of intranasal glulisine vs placebo in 12 subjects with Down syndrome aged ≥ 35 years. Intranasal administration utilized the Impel NeuroPharma I109 Precision Olfactory Delivery (POD®) device. The primary outcomes were the occurrence of any or related adverse and serious adverse events. Secondary post-treatment cognitive outcome measures included performance on the Fuld Object-Memory Evaluation and Rivermead Behavioral Memory Test.

Results: Intranasal glulisine was safe and well tolerated in the Down syndrome population. No adverse or serious adverse events were observed.

Conclusions: Further investigations are necessary to better evaluate the potential cognitive-enhancing role of intranasal insulin in the Down syndrome population. CLINICALTRIALS.

Gov id: NCT02432716.

Conflict of interest statement

Michael Rosenbloom, Terry Barclay, Justin Johnsen, Lauren Erickson, Aleta Svitak, Maria Pyle, William Frey, and Leah R. Hanson have no conflicts of interest that are directly relevant to the content of this study.

Figures

Fig. 1
Fig. 1
Study design

References

    1. Shin M, Besser LM, Kucik JE, et al. Prevalence of Down syndrome among children and adolescents in 10 regions of the United States. Pediatrics. 2009;124(6):1565–1571. doi: 10.1542/peds.2009-0745.
    1. Mohan M, Carpenter PK, Bennett C. Donepezil for dementia in people with Down syndrome. Cochrane Database Syst Rev. 2009;1:CD007178.
    1. Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120(3):885–890. doi: 10.1016/S0006-291X(84)80190-4.
    1. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome. Ann Neurol. 1985;17(3):278–282. doi: 10.1002/ana.410170310.
    1. Lao PJ, Handen BL, Betthauser TJ, et al. Alzheimer-like pattern of hypometabolism emerges with elevated amyloid-beta burden in Down syndrome. J Alzheimers Dis. 2018;61(2):631–644. doi: 10.3233/JAD-170720.
    1. Westerman MA, Cooper-Blacketer D, Mariash A, et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer’s disease. J Neurosci. 2002;22(5):1858–1867. doi: 10.1523/JNEUROSCI.22-05-01858.2002.
    1. Reger MA, Watson GS, Frey WH, 2nd, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging. 2006;27(3):451–458. doi: 10.1016/j.neurobiolaging.2005.03.016.
    1. Reger MA, Craft S. Intranasal insulin administration: a method for dissociating central and peripheral effects of insulin. Drugs Today (Barc). 2006;42(11):729–739. doi: 10.1358/dot.2006.42.11.1007675.
    1. Ke YD, Delerue F, Gladbach A, et al. Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer’s disease. PLoS One. 2009;4(11):e7917. doi: 10.1371/journal.pone.0007917.
    1. Zhang Q, Jiang X, Jiang W, et al. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int J Pharm. 2004;275(1–2):85–96. doi: 10.1016/j.ijpharm.2004.01.039.
    1. Chiu SL, Chen CM, Cline HT. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron. 2008;58(5):708–719. doi: 10.1016/j.neuron.2008.04.014.
    1. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012;69(1):29–38. doi: 10.1001/archneurol.2011.233.
    1. Bingham EM, Hopkins D, Smith D. The role of insulin in human brain glucose metabolism: an 18fluorodeoxyglucose positron emission tomography study. Diabetes. 2002;51(12):3384–3390. doi: 10.2337/diabetes.51.12.3384.
    1. Benedict C, Hallschmid M, Schmitz K, et al. Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology. 2007;32(1):239–243. doi: 10.1038/sj.npp.1301193.
    1. Jafek BW, Linschoten MR, Murrow BW. Anosmia after intranasal zinc gluconate use. Am J Rhinol. 2004;18(3):137–141. doi: 10.1177/194589240401800302.
    1. Davidson TM, Smith WM. The Bradford Hill criteria and zinc-induced anosmia: a causality analysis. Arch Otolaryngol Head Neck Surg. 2010;136(7):673–676. doi: 10.1001/archoto.2010.111.
    1. Rosenbloom MH, Barclay TR, Pyle M, et al. A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer’s disease. CNS Drugs. 2014;28(12):1185–1189. doi: 10.1007/s40263-014-0214-y.
    1. Aldrich FK, Wilson B. Rivermead Behavioural Memory Test for Children (RBMT-C): a preliminary evaluation. Br J Clin Psychol. 1991;30(Pt 2):161–168. doi: 10.1111/j.2044-8260.1991.tb00931.x.
    1. La Rue A, D'Elia LF, Clark EO, et al. Clinical tests of memory in dementia, depression, and healthy aging. Psychol Aging. 1986;1(1):69–77. doi: 10.1037/0882-7974.1.1.69.
    1. Benedict C, Dodt C, Hallschmid M, et al. Immediate but not long-term intranasal administration of insulin raises blood pressure in human beings. Metabolism. 2005;54(10):1356–1361. doi: 10.1016/j.metabol.2005.04.026.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner